PA
IRWD icon

Profund Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Profund Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Sell
77,754
-19,527
-20% -$75.3K 0.01% 751
2026
Q1 		$341K Buy
97,281
+70,798
+267% +$290K 0.01% 676
2025
Q4 		$89.2K Buy
+26,483
New +$68.8K ﹤0.01% 1236
2025
Q1 		– Sell
-51,455
Closed -$228K – 1048
2024
Q4 		$228K Sell
51,455
-30,914
-38% -$125K 0.01% 936
2024
Q3 		$339K Buy
82,369
+6,986
+9% +$37.6K 0.01% 726
2024
Q2 		$491K Sell
75,383
-86,472
-53% -$612K 0.02% 502
2024
Q1 		$1.41M Buy
161,855
+42,371
+35% +$514K 0.05% 252
2023
Q4 		$1.37M Sell
119,484
-31,795
-21% -$315K 0.06% 264
2023
Q3 		$1.46M Buy
151,279
+14,299
+10% +$140K 0.08% 194
2023
Q2 		$1.46M Buy
136,980
+15,485
+13% +$166K 0.08% 220
2023
Q1 		$1.28M Buy
121,495
+103,109
+561% +$1.16M 0.08% 233
2022
Q4 		$228K Buy
18,386
+181
+1% +$2.05K 0.01% 828
2022
Q3 		$189K Sell
18,205
-3,322
-15% -$37.7K 0.01% 837
2022
Q2 		$248K Buy
21,527
+7,261
+51% +$85.5K 0.02% 760
2022
Q1 		$179K Sell
14,266
-966
-6% -$11.1K 0.01% 1287
2021
Q4 		$178K Buy
15,232
+663
+5% +$8.13K 0.01% 1298
2021
Q3 		$190K Sell
14,569
-1,585
-10% -$20.5K 0.01% 1269
2021
Q2 		$208K Buy
16,154
+762
+5% +$8.72K 0.01% 1330
2021
Q1 		$172K Buy
15,392
+928
+6% +$9.8K 0.01% 1278
2020
Q4 		$165K Buy
14,464
+735
+5% +$8.04K 0.01% 1131
2020
Q3 		$123K Sell
13,729
-723
-5% -$7.19K 0.01% 911
2020
Q2 		$149K Buy
14,452
+933
+7% +$9.55K 0.01% 871
2020
Q1 		$136K Sell
13,519
-2,039
-13% -$24K 0.01% 679
2019
Q4 		$207K Buy
15,558
+2,777
+22% +$30.6K 0.01% 1158
2019
Q3 		$110K Sell
12,781
-1,756
-12% -$17.1K 0.01% 1242
2019
Q2 		$159K Sell
14,537
-2,186
-13% -$24.5K 0.01% 1160
2019
Q1 		$190K Sell
16,723
-10,691
-39% -$119K 0.01% 1144
2018
Q4 		$238K Sell
27,414
-4,425
-14% -$50.8K 0.01% 927
2018
Q3 		$492K Buy
+31,839
New +$503K 0.02% 834

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Profund Advisors's IRWD Position: Q2 2026 in Review

Profund Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 20% in Q2 2026, selling an estimated $75.3K and leaving 77,754 shares worth $327K. The position accounts for 0.01% of the portfolio, ranked #751.

Profund Advisors first reported a position in IRWD in Q3 2018 and has held it in 29 quarters since. The position peaked at $1.46M in Q2 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Profund Advisors held 77,754 shares of Ironwood Pharmaceuticals worth $327K as of Q2 2026.
  • Profund Advisors sold 19,527 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $75.3K.
  • Ironwood Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #751 holding.
  • Profund Advisors first reported a position in Ironwood Pharmaceuticals in Q3 2018 and has held it in 29 quarters since.
  • Profund Advisors's Ironwood Pharmaceuticals position peaked at $1.46M in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.